指南与共识泌尿生殖与妇科肿瘤放疗放疗物理与技术

粒子束放疗在妇科肿瘤中的应用:范围综述与专家意见

Particle-Beam Radiation Therapy for Gynecologic Cancers: A Scoping Review and Expert Opinion by the Particle Therapy Cooperative Group - Gynecologic Subcommittee.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2026-08-14

粒子治疗协作组妇科分委会开展范围综述,系统评估粒子束放疗在妇科肿瘤中的证据。检索四个数据库共纳入41项研究,碳离子放疗主要用于抗拒性肿瘤根治,质子束放疗多用于术后和复发。专家认为需标准化方案并开展前瞻性研究。

要点

  • 碳离子放疗支持用于抗拒性妇科肿瘤根治及不可切除复发。
  • 质子束放疗证据增加,尤用于辅助和再照射以降低毒性。
  • 需标准化方案、集中管理罕见妇科肿瘤并开展前瞻性研究。

核心结论

  • 当前证据支持碳离子放疗用于抗拒性妇科恶性肿瘤根治和不可切除复发。
  • increasing evidence supports proton therapy, particularly as adjuvant and reirradiation therapy, to reduce toxicity and improve quality of life.
  • 需标准化治疗方案、在粒子治疗协作组网络内集中管理罕见妇科肿瘤并开展足够效力的前瞻性研究。

研究设计与样本

  • 粒子治疗协作组妇科分委会开展范围综述,遵循PRISMA-ScR指南。
  • 系统检索Medline、Embase、Web of Science和Cochrane Library,采用PICOS框架两阶段筛选。
  • 纳入41项研究,发表年份1976至2025年,63.4%发表于2018至2025年。
  • 63.4%研究来自日本粒子治疗中心,65.8%(n=27)为队列研究或病例系列。
  • 29.3%(n=12)为1期和/或2期临床试验,方法学质量用JBI病例系列评价工具评估。

主要发现

  • 碳离子放疗是最常用模式,主要用于抗拒性妇科肿瘤(包括黑色素瘤和局部晚期宫颈癌)的根治性治疗。
  • 新兴数据提示消融性粒子治疗对不适合常规治疗的寡转移卵巢疾病有潜在作用。
  • 质子束放疗主要用于术后和复发疾病场景。

临床怎么用

  • 碳离子放疗可用于抗拒性妇科恶性肿瘤的根治性治疗及不可切除复发的处理。
  • 质子束放疗可考虑用于术后辅助和再照射,以降低毒性并改善生活质量。
  • 寡转移卵巢疾病不适合常规治疗时,可评估消融性粒子治疗的潜在价值。

局限性

  • 多数研究为队列研究或病例系列(65.8%),证据等级有限。
  • 研究多来自日本粒子治疗中心(63.4%),存在地域集中性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the current clinical applications of particle therapy in gynecologic oncology, the Particle Therapy Cooperative Group gynecologic subcommittee conducted a scoping review to systematically assess the available evidence and define the evolving role of particle-beam radiation therapy (RT) across gynecologic cancer subtypes. METHODS AND MATERIALS: A systematic literature search was performed in Medline, Embase, Web of Science, and the Cochrane Library in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines. Study selection followed a population, intervention, comparison, outcomes, and study design framework and was conducted in 2 sequential screening phases. The methodological quality of the included studies was assessed with the Joanna Briggs Institute critical appraisal tool for case series. RESULTS: Of 414 unique records identified, 41 were included in the final analysis. Publication years ranged from 1976 to 2025, with most studies (63.4%) published between 2018 and 2025; most (63.4%) were from Japanese particle therapy centers, and most (n = 27, 65.8%) were cohort studies or case series, including retrospective, prospective, and pair-matched cohorts, pooled analyses, and case series. Phase 1 and/or 2 clinical trials accounted for 29.3% of the studies (n = 12). Carbon-ion RT was the most commonly used modality, primarily for radical treatment of radioresistant gynecologic tumors, including melanomas and locally advanced cervical cancer. Emerging data suggest a potential role for ablative particle therapy in oligometastatic ovarian disease not suitable for conventional treatments. Proton beam RT was predominantly applied in the postoperative and recurrent disease settings. CONCLUSIONS: Current evidence supports the use of carbon-ion RT for the radical management of radioresistant gynecologic malignancies and unresectable recurrences. Increasing evidence also supports proton therapy, particularly as adjuvant and reirradiation therapy, to reduce toxicity and improve quality of life. Standardization of treatment protocols, centralization of rare gynecologic cancer management within the Particle Therapy Cooperative Group network, and adequately powered prospective studies are needed to optimize patient selection and refine clinical indications.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Barcellini A, Contreras JA, Krause KJ, et al. Particle-Beam Radiation Therapy for Gynecologic Cancers: A Scoping Review and Expert Opinion by the Particle Therapy Cooperative Group - Gynecologic Subcommittee. Int J Radiat Oncol Biol Phys. 2026. PMID: 42600706. doi:10.1016/j.ijrobp.2026.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。